SYS-CON MEDIA Authors: Bob Gourley, Lori MacVittie, RealWire News Distribution, Cynthia Dunlop, Mark O'Neill

News Feed Item

RNAi for Therapeutic Applications: Technology and Market 2014-2024

LONDON, February 20, 2014 /PRNewswire/ --

Potential of RNAi therapies - new analysis showing R&D, trends, and revenue prospects

Where are RNA interference based medicines going? For those treatments you can get new sales predictions and explore developments. You unlock that emerging medical industry. And you assess its results, trends, technologies, potentials, and opportunities.

Visiongain's new report forecasts those revenues to 2024 at overall world market, product, and national level. Discover now what's happening. You stay ahead in data, then, helping your influence. Hear about potential gains for companies pioneering those drugs.

Forecasts to 2024 and other analyses predict and explain the RNAi-based drug market

Why miss data you need? Why struggle to find it? Instead our report gives you revenue forecasts to 2024, also with historical data, growth rates, and market shares.

Also you investigate research and development, assessing its potential. The study also gives 59 tables, 26 charts, and interviews with two companies.

Prospects for that technology - analyses showing where the money lies

The new report shows the lucrative opportunities for ribonucleic acid interference (RNAi) technologies. And you discover forecasting for both optimistic and conservative scenarios. Those analyses predict how much money the pharma industry can earn.

See how that original analysis can benefit your reputation for commercial insight.

And the following sections explain what our investigation gives to help your research, analyses, and decisions.

Sales predictions for that world market and its products

What secrets influence RNAi medicine's future? Once companies overcome technological challenges - gaining regulatory approval - patients will benefit. Discover in our report overall world revenue estimates to 2024 with discussions of trends and prospects.

Also you find individual revenue forecasts to 2024 for 11 therapeutic agents, including these:
• PF-655
• QPI-1007
• SYL040012
• ALN-RSV01
• ARC-520
• SPC3649 (Miravirsen).

There you assess advances and outlooks for those biopharmaceuticals. Hear where you could profit.

Where lie the best prospects? There you explore outlooks for sales, assessing where revenues and profits lie. Find data on gene silencing and its business potential.

For that biotechnology, our work also shows you geographical revenue predictions.

To see an exec summary of this report please email Sara Peerun on sara.peerun@visiongainglobal.com

National markets - what outlooks to 2024 for RNAi drug revenues?

Advances in science, biotechnology and pharma expand possibilities of medicines harnessing RNAi interference. You gain feel for those technologies' revenue prospects.

So our analyses give you individual revenue forecasts to 2024 for 11 national markets:
United States (US)
Japan
• EU leaders - Germany, France, the UK, Italy, and Spain (EU5)
• BRIC nations - Brazil, Russia, India, and China.

There you find regions with highest revenues, demand, and potential sales growth. Our work explains. You see international prospects.

Explore, too, how RNAi technology can benefit its developers, producers, marketers, and sellers. Our work shows you, also discussing technological progress and its meaning.

Developing products - discover trends, innovations, and progress

You also investigate R&D, finding technological and commercial possibilities. Our report discusses these advances and others:
• Short or small interfering RNA (siRNA)
• Expressed/DNA-directed RNAi (ddRNAi)
• Locked nucleic acid (LNA) and short hairpin RNA (shRNA), inc. viral vectors
• microRNA (miRNA) - natural gene expression regulators
• Novel drug delivery, including nanoparticle-based systems.

And it explores applications such as these:
• Ocular disorders, inc. age-related macular degeneration (AMD) and glaucoma
• Lung conditions, inc. respiratory syncytial virus (RSV) infection
• Infectious diseases, inc. hepatitis B and C virus (HBV and HCV) infections
• Kidney disease, inc. delayed graft function (DGF)
• Cancers - advantages in oncology.

Despite difficulties, pre-clinical and clinical developments there hold strength, variety, and promise. See what's possible for big pharma and specialists in biological drugs (biologics).

And what events change that industry? Our work shows you, discussing trends and needs.

Developments, challenges, and effects influencing RNAi technologies

The report explains forces affecting that industry and market from 2014, including these:
• Reducing side effects, including adverse immune reactions
• Orphan drug designation for competitive advantages
• Personalised therapy, inc. targeting multiple cancer subtypes
• Prospects for combination therapy
• Strategic alliances, out-licensing technology, and contract manufacturing.

What happens next? There discover what the present and future hold. You examine what encourages and restrains players in that sector, and affects its results.

To see an exec summary of this report please email Sara Peerun on sara.peerun@visiongainglobal.com

Analysis of companies leading that biotechnological field

From this decade, technological developments and needs of patients, doctors, and payers will encourage investments, medical advances, and sales of RNAi-based therapeutics.

And there you examine activities of many organisations, including these:
• Alnylam Pharmaceuticals
• Silence Therapeutics
• RXi Pharmaceuticals
• Quark Pharmaceuticals
• Santaris Pharma.

You find 119 organisations covered in the study. You also get interviews with authorities in that industry. Discover what participants do, say, and think.

Ways RNAi for Therapeutic Applications: Technology and Market 2014-2024 helps

In particular, our new investigation gives this knowledge to help your work:
• Revenues there to 2024 at world level and for 11 expected products - assess outlooks for approvals, production, marketing, and sales
• Forecasts to 2024 for 11 national markets in the Americas, Europe, and Asia - explore developed and developing countries for future revenues
• Activities of companies in that biomedical field - investigate technologies, R&D pipelines, drug candidates, strategies, and prospects.

Data found nowhere else, helping your searches, analyses, and plans

Our study gives independent analysis. There you receive competitive intelligence found only in our work, finding where progress and money lie. You explore commercial outlooks.

So with our findings you're less likely to miss opportunity. Being free to choose, then, our study shows how you could save time and effort, also helping planning, decisions, and influence.

This new report is for everyone analysing emerging technologies in biopharma. For RNAi-based medicines you explore R&D trends, issues, and sales predictions. Avoid missing out, then - please order now.

To request an exec summary of this report please email Sara Peerun at            sara.peerun@visiongainglobal.com or call Tel : +44 (0) 20 7336 6100

Or click on http://www.visiongain.com/Report/1204/RNAi-for-Therapeutic-Applications-Technology-and-Market-2014-2024

Companies Listed

Acuity Pharmaceuticals
Aegera Therapeutics
Agilent Technologies
Alcon
Allele Biotechnology
Allergan
Alnylam Pharmaceuticals
Altogen Labs
Antisense Therapeutics
Antisoma Research
Archemix Corporation
ArmaGen Technologies
Arrowhead Research Corporation
Ascletis Pharmaceuticals
AstraZeneca
Atlantic Pharmaceuticals
Atugen AG
Avecia OligoMedicines
AVI BioPharma
Bayer
Bio Synthesis
Biocon
Biogen Idec
Biomatik Corporation
Biomics Biotechnologies
Bionexus
BioSpring
Bristol-Myers Squibb
Calando Pharmaceuticals
Carnegie Institution for Science
Chinese University of Hong Kong
Cubist Pharmaceuticals
Dainippon Sumitomo Pharma
Dharmacon RNAi Technologies
Eleos
Eli Lilly
Enzo Therapeutics
Enzon Pharmaceuticals
Eurofins MWG-Biotech
Eurogentec
European Commission
European Medicines Agency (EMA)
European Union (EU)
Expression Genetics
Eyetech Pharmaceuticals
EZBiolab
Food and Drug Administration (US FDA)
Gene Link
Gene Signal International
GeneCare Research Institute
GeneDesign
Genentech
Genta Incorporated
Genzyme
Girindus America
Gradalis
GlaxoSmithKline (GSK)
Halo-Bio RNAi Therapeutics
Integrated DNA Technologies
Intradigm Corporation
Invitrogen
Isarna Therapeutics
ISIS Pharmaceuticals
Kyowa Hakko Kirin
Life Technologies
Lorus Therapeutics
Marina Biotech
Mary Crowley Cancer Research Centre
Max Planck Institute
MedImmune
Medtronic
Merck & Co.
Merz Pharmaceuticals
Nitto Denko Corporation
Novartis
NovaRx Corporation
Novosom
Noxxon Pharma
Ohio State University (OSU)
Oligoengine
OncoGenex Technologies
Ophthotech Corporation
OPKO Health
OSI Pharmaceuticals
Pfizer
Protiva Biotherapeutics
Qiagen
Quark Biotech
Quark Pharmaceuticals
Regado Biosciences
Regeneron Pharmaceuticals
Ribopharma AG
RiboTask
RXi Pharmaceuticals
Roche
SABiosciences
Samyang Corporation
Santaris Pharma
Sanofi
Shire
Sigma Aldrich
Silence Therapeutics
Sirnaomics
Sirna Therapeutics
Spanish Society for Glaucoma
Solvay Group
Suzhou Ribo Life Sciences
Sylentis
Talon Pharmaceuticals
Takeda
Targeted Genetics Corporation
Tekmira Pharmaceuticals
Teva Pharmaceuticals
The Medicines Company
Thermo Scientific
Traversa Therapeutics
University of Bayreuth
University of Massachusetts Medical School
VIRxSYS
World Health Organization (WHO)
Zeltia Group

To see an exec summary of this report please email Sara Peerun on sara.peerun@visiongainglobal.com

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.